Loading clinical trials...
Loading clinical trials...
Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS): a Randomized Controlled Trial
A randomized controlled trial will be conducted. Patients with asymptomatic intracranial / carotid stenosis will be randomized into two arms (1:1): an intervention arm and a control arm. Patients in the intervention arm will be treated with standard medical treatment combined with Natto Products V, whereas Patient in the control arm will be treated with only standard medical treatment . And the impact of Natto Products V on improving cerebral blood flow and cognitive function in patients with asymptomatic intracranial / carotid stenosis will be assessed by neuropsychological scale and multimode magnetic resonance imaging.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Second Affilated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Start Date
January 13, 2022
Primary Completion Date
July 31, 2023
Completion Date
December 31, 2023
Last Updated
April 18, 2023
100
ESTIMATED participants
Nattokinase
DRUG
Placebo
DRUG
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04653012
NCT07071181
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions